Tumor Necrosis Factor (TNF) Inhibitor Drugs Market (By Product: Simponi/Simponi Aria, Remicade, Enbrel, Cimzia, Humira, Biosimilars; By Application: Psoriatic Arthritis, Crohn’s Disease, Rheumatoid Arthritis, Psoriasis, Juvenile Idiopathic Arthritis, Hidradenitis Suppurativa, Ulcerative Colitis, Ankylosing Spondylitis, Others; By Sales Channel: Online Pharmacies, Specialty Pharmacies, Hospital Pharmacies) - Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 - 2026

CHAPTER 1. INDUSTRY OVERVIEW

1.1. Definition and Scope
1.1.1. Definition of Tumor Necrosis Factor (TNF) Inhibitor Drugs
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Tumor Necrosis Factor (TNF) Inhibitor Drugs Market By Product
1.2.2.1. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Revenue and Growth Rate Comparison By Product (2015-2026)
1.2.2.2. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Revenue Share By Product in 2017
1.2.2.3. Simponi/Simponi Aria
1.2.2.4. Remicade
1.2.2.5. Enbrel
1.2.2.6. Cimzia
1.2.2.7. Humira
1.2.2.8. Biosimilars
1.2.3. Tumor Necrosis Factor (TNF) Inhibitor Drugs Market By Application
1.2.3.1. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Revenue and Growth Rate Comparison By Application (2015-2026)
1.2.3.2. Psoriatic Arthritis
1.2.3.3. Crohn’s Disease
1.2.3.4. Rheumatoid Arthritis
1.2.3.5. Psoriasis
1.2.3.6. Juvenile Idiopathic Arthritis
1.2.3.7. Hidradenitis Suppurativa
1.2.3.8. Ulcerative Colitis
1.2.3.9. Ankylosing Spondylitis
1.2.3.10. Others
1.2.4. Tumor Necrosis Factor (TNF) Inhibitor Drugs Market By Sales Channel
1.2.4.1. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Revenue and Growth Rate Comparison By Sales Channel (2015-2026)
1.2.4.2. Online Pharmacies
1.2.4.3. Specialty Pharmacies
1.2.4.4. Hospital Pharmacies
1.2.5. Tumor Necrosis Factor (TNF) Inhibitor Drugs Market by Geography
1.2.5.1. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.5.2. North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Revenue and Growth Rate (2015-2026)
1.2.5.3. Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Revenue and Growth Rate (2015-2026)
1.2.5.4. Asia-Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Revenue and Growth Rate (2015-2026)
1.2.5.5. Latin America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Revenue and Growth Rate (2015-2026)
1.2.5.6. Middle East and Africa (MEA) Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS

2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS

3.1. Capacity and Commercial Production Date of Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Major Manufacturers in 2017
3.3. R&D Status and Technology Product of Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Major Manufacturers in 2017

CHAPTER 4. TUMOR NECROSIS FACTOR (TNF) INHIBITOR DRUGS MARKET BY PRODUCT

4.1. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue By Product
4.2. Simponi/Simponi Aria
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Remicade
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.4. Enbrel
4.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.5. Cimzia
4.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.6. Humira
4.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.7. Biosimilars
4.7.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.7.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 5. TUMOR NECROSIS FACTOR (TNF) INHIBITOR DRUGS MARKET BY APPLICATION

5.1. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue By Application
5.2. Psoriatic Arthritis
5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. Crohn’s Disease
5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.4. Rheumatoid Arthritis
5.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.5. Psoriasis
5.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.6. Juvenile Idiopathic Arthritis
5.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.7. Hidradenitis Suppurativa
5.7.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.7.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.8. Ulcerative Colitis
5.8.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.8.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.9. Ankylosing Spondylitis
5.9.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.9.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.10. Others
5.10.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.10.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 6. TUMOR NECROSIS FACTOR (TNF) INHIBITOR DRUGS MARKET BY SALES CHANNEL

6.1. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue By Sales Channel
6.2. Online Pharmacies
6.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.3. Specialty Pharmacies
6.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.4. Hospital Pharmacies
6.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 7. NORTH AMERICA TUMOR NECROSIS FACTOR (TNF) INHIBITOR DRUGS MARKET BY COUNTRY

7.1. North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2. North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Revenue Share Comparison, 2015 & 2026 (%)
7.3. U.S.
7.3.1. U.S. Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
7.3.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
7.3.3. Market Revenue and Forecast By Sales Channel, 2015 - 2026 ($Million)
7.4. Canada
7.4.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
7.4.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
7.4.3. Market Revenue and Forecast By Sales Channel, 2015 - 2026 ($Million)
7.5. Mexico
7.5.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
7.5.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
7.5.3. Market Revenue and Forecast By Sales Channel, 2015 - 2026 ($Million)

CHAPTER 8. EUROPE TUMOR NECROSIS FACTOR (TNF) INHIBITOR DRUGS MARKET BY COUNTRY

8.1. Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. UK
8.3.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
8.3.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.3.3. Market Revenue and Forecast By Sales Channel, 2015 - 2026 ($Million)
8.4. Germany
8.4.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
8.4.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.4.3. Market Revenue and Forecast By Sales Channel, 2015 - 2026 ($Million)
8.5. France
8.5.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
8.5.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.5.3. Market Revenue and Forecast By Sales Channel, 2015 - 2026 ($Million)
8.6. Spain
8.6.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
8.6.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.6.3. Market Revenue and Forecast By Sales Channel, 2015 - 2026 ($Million)
8.7. Rest of Europe
8.7.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
8.7.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.7.3. Market Revenue and Forecast By Sales Channel, 2015 - 2026 ($Million)

CHAPTER 9. ASIA-PACIFIC TUMOR NECROSIS FACTOR (TNF) INHIBITOR DRUGS MARKET BY COUNTRY

9.1. Asia-Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Asia-Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. China
9.3.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
9.3.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.3.3. Market Revenue and Forecast By Sales Channel, 2015 - 2026 ($Million)
9.4. Japan
9.4.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
9.4.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.4.3. Market Revenue and Forecast By Sales Channel, 2015 - 2026 ($Million)
9.5. India
9.5.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
9.5.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.5.3. Market Revenue and Forecast By Sales Channel, 2015 - 2026 ($Million)
9.6. Australia
9.6.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
9.6.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.6.3. Market Revenue and Forecast By Sales Channel, 2015 - 2026 ($Million)
9.7. South Korea
9.7.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
9.7.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.7.3. Market Revenue and Forecast By Sales Channel, 2015 - 2026 ($Million)
9.8. Rest of Asia-Pacific
9.8.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
9.8.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.8.3. Market Revenue and Forecast By Sales Channel, 2015 - 2026 ($Million)

CHAPTER 10. LATIN AMERICA TUMOR NECROSIS FACTOR (TNF) INHIBITOR DRUGS MARKET BY COUNTRY

10.1. Latin America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Latin America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. Brazil
10.3.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
10.3.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
10.3.3. Market Revenue and Forecast By Sales Channel, 2015 - 2026 ($Million)
10.4. Argentina
10.4.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
10.4.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
10.4.3. Market Revenue and Forecast By Sales Channel, 2015 - 2026 ($Million)
10.5. Rest of Latin America
10.5.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
10.5.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
10.5.3. Market Revenue and Forecast By Sales Channel, 2015 - 2026 ($Million)

CHAPTER 11. MIDDLE EAST TUMOR NECROSIS FACTOR (TNF) INHIBITOR DRUGS MARKET BY COUNTRY

11.1. Middle East Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Middle East Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. Saudi Arabia
11.3.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
11.3.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
11.3.3. Market Revenue and Forecast By Sales Channel, 2015 - 2026 ($Million)
11.4. UAE
11.4.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
11.4.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
11.4.3. Market Revenue and Forecast By Sales Channel, 2015 - 2026 ($Million)
11.5. Rest of Middle East
11.5.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
11.5.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
11.5.3. Market Revenue and Forecast By Sales Channel, 2015 - 2026 ($Million)

CHAPTER 12. AFRICA TUMOR NECROSIS FACTOR (TNF) INHIBITOR DRUGS MARKET BY COUNTRY

12.1. Africa Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Revenue and Growth Rate, 2015 - 2026 ($Million)
12.2. Africa Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Revenue Share Comparison, 2015 & 2026 (%)
12.3. South Africa
12.3.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
12.3.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
12.3.3. Market Revenue and Forecast By Sales Channel, 2015 - 2026 ($Million)
12.4. Egypt
12.4.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
12.4.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
12.4.3. Market Revenue and Forecast By Sales Channel, 2015 - 2026 ($Million)
12.5. Rest of Africa
12.5.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
12.5.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
12.5.3. Market Revenue and Forecast By Sales Channel, 2015 - 2026 ($Million)

CHAPTER 13. COMPANY PROFILE

13.1. Amgen Inc.
13.1.1. Company Snapshot
13.1.2. Overview
13.1.3. Financial Overview
13.1.4. Type Portfolio
13.1.5. Key Developments
13.1.6. Strategies
13.2. AbbVie Inc.
13.2.1. Company Snapshot
13.2.2. Overview
13.2.3. Financial Overview
13.2.4. Type Portfolio
13.2.5. Key Developments
13.2.6. Strategies
13.3. Pfizer, Inc.
13.3.1. Company Snapshot
13.3.2. Overview
13.3.3. Financial Overview
13.3.4. Type Portfolio
13.3.5. Key Developments
13.3.6. Strategies
13.4. Novartis International AG
13.4.1. Company Snapshot
13.4.2. Overview
13.4.3. Financial Overview
13.4.4. Type Portfolio
13.4.5. Key Developments
13.4.6. Strategies
13.5. Johnson & Johnson Services, Inc.
13.5.1. Company Snapshot
13.5.2. Overview
13.5.3. Financial Overview
13.5.4. Type Portfolio
13.5.5. Key Developments
13.5.6. Strategies
13.6. UCB S.A.
13.6.1. Company Snapshot
13.6.2. Overview
13.6.3. Financial Overview
13.6.4. Type Portfolio
13.6.5. Key Developments
13.6.6. Strategies
13.7. Merck & co., Inc.
13.7.1. Company Snapshot
13.7.2. Overview
13.7.3. Financial Overview
13.7.4. Type Portfolio
13.7.5. Key Developments
13.7.6. Strategies
13.8. Others
13.8.1. Company Snapshot
13.8.2. Overview
13.8.3. Financial Overview
13.8.4. Type Portfolio
13.8.5. Key Developments
13.8.6. Strategies

CHAPTER 14. RESEARCH APPROACH

14.1. Research Methodology
14.1.1. Initial Data Search
14.1.2. Secondary Research
14.1.3. Primary Research
14.2. Assumptions and Scope